Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02221648
Recruitment Status : Terminated (PI retired and moved- funding sponsor contacted and Oked)
First Posted : August 20, 2014
Results First Posted : March 8, 2016
Last Update Posted : July 20, 2016
Sponsor:
Collaborator:
Ipsen
Information provided by (Responsible Party):
Yale University

Brief Summary:

The scientific aim of this study is to investigate the efficacy of abobotulinumtoxinA (Dysport - Ipsen Pharmaceuticals) in chronic low back pain.

The investigators hypothesis is that injection of Dysport brand of botulinum toxin type A into erector spinae muscles (extensors of the spine) can relieve low back pain through anti-spasm and analgesic effect of botulinum toxin.


Condition or disease Intervention/treatment Phase
Lower Back Pain Drug: Placebo Drug: AbobotulinumtoxinA Treatment Phase 2

Detailed Description:

This is an investigator initiated, randomized, double blind, placebo-controlled study. A total of 90 patients will be enrolled in the study. The study will be conducted over 4 months. It includes 4 visits and 4 telephone calls. Patients with chronic low back pain (>3 months) who meet inclusion and exclusion criteria and wish to participate in the study may be enrolled. Those who become enrolled will be scheduled for a baseline visit (Week 0). During the baseline visit, subjects will be given the official approved consent form to read and ask questions. Participants to this study will also receive a copy of the Dysport Risk Evaluation and Mitigation Strategy (REMS) statement. After obtaining informed consent signed by the subject, the subjects will be randomization into the Dysport or placebo group. The randomizing will be performed by a nurse and the information will be kept in a pass-worded computer. Blinding means that neither the participant nor the clinical rater will know which group the participant has been initially been assigned.

Each subject will have a neurological examination and fill a demographic form and complete four rating questionnaires (appendix II-V). These include a visual analogue scale for pain (0 to 10) and three quality of life questionnaires which depict quality of life (the American Chronic Pain Association's Quality of Life Scale), how pain affects ability to manage everyday life (Oswestry Low Back Pain Disability Questionnaire), and overall physical and emotional health (Short Form-36). Patients will then receive an injection of either abobotulinumA (Dysport) or normal saline. Dysport or saline will be administered into the paraspinal muscles (extensors or erector spinae) at five levels (L1-L5), regardless of pain location. In the case of unilateral pain, this would amount to 500 units total, and in the case of bilateral pain, to 1000 units total, of Dysport per session.

The primary outcome of the study is number of patients with VAS < 4 ( no or subtle pain) at week 6 after placebo or Dysport injection.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain
Study Start Date : December 2012
Actual Primary Completion Date : September 2015
Actual Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Back Pain Botox

Arm Intervention/treatment
Placebo Comparator: Placebo
Subjects will be randomization to receive injections with either the study drug (abobotulinumtoxinA) or the placebo group. The subjects will be blinded to which intervention they will receive.
Drug: Placebo
Subjects will be randomization to receive either the study drug or the placebo group.

Active Comparator: AbobotulinumtoxinA Treatment
Subjects will be randomized to receive intervention injections with the study drug arbobotulinumtoxinA.
Drug: AbobotulinumtoxinA Treatment
Subjects receive intervention injections with the study drug arbobotulinumtoxinA.
Other Name: Dysport




Primary Outcome Measures :
  1. Proportion of Participants With Mild or no Pain on Visual Analog Scale (VAS) [ Time Frame: 6 weeks ]
    The primary outcome measure in this protocol is the proportion of subjects that have VAS <4 (patients with no or mild pain) at week 6. The pain VAS is a continuous scale comprised of a line 10 centimeters in length, anchored by 2 verbal descriptors, one for each symptom extreme. For pain intensity, the scale is anchored by "no pain" (score of 0) and "worst imaginable pain" (score of 10).


Secondary Outcome Measures :
  1. Number of Patients With Improved Pain Using the Patient Global Impression of Change (PGIC) [ Time Frame: 6 weeks ]

    The PGIC is a 7 point scale that requires the clinician to assess how much the patient's pain has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as:

    No change (or condition has gotten worse) (1) Almost the same, hardly any change at all (2) A little better, but no noticeable change (3) Somewhat better, but the change has not made any real difference (4) Moderately better, and a slight but noticeable change (5) Better and a definite improvement that has made a real and worthwhile difference (6) A great deal better and a considerable improvement that has made all the difference (7)

    This outcome is number of patients who chose a 6 or above on the PGIC 6 weeks after treatment


  2. Number of Subjects Showing Improvement on Quality of Life Scale for Pain [ Time Frame: 6 weeks ]
    The Quality of Life Scale: A Measure of Function for People With Pain was developed by the American Chronic Pain Association (ACPA). The patient is asked to rank their quality of life on a scale of zero (non-functioning) to 10 (normal quality of life). Improvement was defined as 2 or more grades of improvement on the scale.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18-80, all ethnic groups, races, both sexes.
  • Diagnosis of chronic low back pain (longer than 3 months).
  • Pain of moderate to severe intensity (VAS 4 or higher).
  • Subjects who are able to read, speak, and understand English.

Exclusion Criteria:

Existing significant acute medical condition (i.e. cardiovascular, endocrine, hematologic, neoplastic, infectious, or autoimmune disorders).

  • Hypersensitivity to any botulinum toxin product or is recipient
  • Allergy to albumin. Lactose or cow milk protein
  • Infection in the proposed injection site.
  • Pregnancy or planned pregnancy (determined by urine pregnancy test). The women of childbearing age should use a reliable mode of contraception during the study period (abstinence, etc).
  • Active breast feeding.
  • Enrollment in any clinical trial (currently or within the past 3 months) in which treatments are imposed by a protocol.
  • Patients taking high doses of aminoglycosides or other drugs affecting the function of neuromuscular junction (anticholinergics , muscle relaxants)
  • Subjects who are younger than 18 years of age.
  • Neuromuscular-junction disorders and motor neuron disease such as Amyotrophic Lateral Sclerosis.
  • Evidence of acute pathology on neuro-imaging.
  • Axis I diagnosis determined by a neurologist or psychiatrist.
  • Anesthetic medications within two weeks and corticosteroid injections within 4 weeks of enrollment.
  • Received botulinum toxin injections in the past 3 months.
  • History of low back surgery , evidence of acute disc or severe lumbar stenosis in MRI

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02221648


Locations
Layout table for location information
United States, Connecticut
Yale Medical Group
New Haven, Connecticut, United States, 06520
Sponsors and Collaborators
Yale University
Ipsen
Investigators
Layout table for investigator information
Principal Investigator: Bahman Jabbari, MD Yale University
Layout table for additonal information
Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT02221648    
Other Study ID Numbers: 1210011010
First Posted: August 20, 2014    Key Record Dates
Results First Posted: March 8, 2016
Last Update Posted: July 20, 2016
Last Verified: July 2016
Keywords provided by Yale University:
Back
Pain
Muscle
Additional relevant MeSH terms:
Layout table for MeSH terms
Back Pain
Low Back Pain
Pain
Neurologic Manifestations
abobotulinumtoxinA
Botulinum Toxins, Type A
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents